Nasdaq:US$8.83 (+0.24) | HKEX:HK$14.50 (-0.36) | AIM:£1.44 (-0.02)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors